Search

Your search keyword '"Greenwald, Maria W."' showing total 9 results
Start Over Author "Greenwald, Maria W."
9 results on '"Greenwald, Maria W."'

5. Rituximab for Rheumatoid Arthritis Refractory to Anti–Tumor Necrosis Factor Therapy: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating Primary Efficacy and Safety at Twenty-Four Weeks

Author

Cohen, Stanley B., Emery, Paul, Greenwald, Maria W., Dougados, Maxime, Furie, Richard A., Genovese, Mark C., Keystone, Edward C., Loveless, James E., Burmester, Gerd-Rüdiger, Cravets, Matthew W., Hessey, Eva W., Shaw, Timothy, and Totoritis, Mark C.

Published
2006

6. Effects of Prasterone on Disease Activity and Symptoms in Women With Active Systemic Lupus Erythematosus: Results of a Multicenter Randomized, Double-Blind, Placebo-Controlled Trial

Author

Petri, Michelle A., Mease, Philip J., Merrill, Joan T., Lahita, Robert G., Iannini, Mark J., Yocum, David E., Ginzler, Ellen M., Katz, Robert S., Gluck, Oscar S., Genovese, Mark C., Van Vollenhoven, Ronald, Kalunian, Kenneth C., Manzi, Susan, Greenwald, Maria W., Buyon, Jill P., Olsen, Nancy J., Schiff, Michael H., Kavanaugh, Arthur F., Caldwell, Jacques R., Ramsey-Goldman, Rosalind, St. Clair, E. William, Goldman, Allan L., Egan, Rita M., Polisson, Richard P., Moder, Kevin G., Rothfield, Naomi F., Spencer, Robert T., Hobbs, Kathryn, Fessler, Barri J., Calabrese, Leonard H., Moreland, Larry W., Cohen, Stanley B., Quarles, Betty J., Strand, Vibeke, Gurwith, Marc, and Schwartz, Kenneth E.

Published
2004

9. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.

Author

Pritchard, Charles H., Greenwald, Maria W., Kremer, Joel M., Gaylis, Norman B., Rigby, William, Zlotnick, Steve, Chung, Carol, Jaber, Birgit, and Reiss, William

Subjects
*RITUXIMAB, *RHEUMATOID arthritis treatment, *INFUSION therapy, *DRUG administration, *PHARMACODYNAMICS
Abstract

Background As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safety of infusing rituximab at a faster rate for an infusion period of 2 hours in patients with RA. Methods Patients with an inadequate response to anti-TNF who were rituximab-naive or -experienced received 2 courses of rituximab: Infusion 1 (Day 1) was administered over the standard 4.25 hours, and Infusions 2 (Day 15), 3 (Day 168) and 4 (Day 182) were administered over a faster 2-hour period. The primary endpoint was incidence of infusion-related reactions (IRRs) associated with Infusion 2. Results Of the 351 patients enrolled, 87% and 13% were rituximab-naive and -experienced, respectively. The incidence (95% CI) of IRRs associated with Infusion 1 was 16.2% (12.5%, 20.5%) and consistent with weighted historical incidence of 20.7% (19.4%, 22.1%). The incidence (95% CI) of IRRs associated with Infusions 2, 3, and 4 compared with respective weighted historical incidences at the standard infusion rate was 6.5% (4.1%, 9.7%) vs 8.1% (7.2%, 9.1%); 5.9% (3.5%, 9.3%) vs 11.5% (10.3%, 12.8%); and 0.7 (0.1%, 2.6%) vs 5.0% (4.2%, 6.0%), respectively. All IRRs were grade 1 or 2, except for 3 grade 3 IRRs associated with Infusion 1 and 2 grade 3 IRRs associated with Infusion 2. Four patients experienced a total of 5 grade 3 IRRs; 3 of these patients continued on to received subsequent infusions at the faster rate. There were no serious IRRs. Conclusion This study demonstrated that rituximab can be administered at the faster infusion rate at the second and subsequent infusions without increasing the rate or severity of IRRs. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results